BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 7586613)

  • 21. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.
    Croxatto HB; Salvatierra AM; Croxatto HD; Fuentealba B
    Hum Reprod; 1993 Feb; 8(2):201-7. PubMed ID: 8473419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
    Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
    Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of low daily doses of mifepristone on ovarian function and endometrial development.
    Danielsson KG; Swahn ML; Westlund P; Johannisson E; Seppälä M; Bygdeman M
    Hum Reprod; 1997 Jan; 12(1):124-31. PubMed ID: 9043916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy.
    Batista MC; Cartledge TP; Zellmer AW; Merino MJ; Axiotis C; Loriaux DL; Nieman LK
    Am J Obstet Gynecol; 1992 Jul; 167(1):60-5. PubMed ID: 1442957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS; Schneider K; Taubert HD
    Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
    Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
    J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single dose of mifepristone (200 mg) in the immediate preovulatory phase offers contraceptive potential without cycle disruption.
    Brown A; Williams A; Cameron S; Morrow S; Baird DT
    Contraception; 2003 Sep; 68(3):203-9. PubMed ID: 14561541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R; Kuhl H; Taubert HD; Sandow J
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days.
    Baird DT; Thong KJ; Hall C; Cameron ST
    Hum Reprod; 1995 Sep; 10(9):2270-6. PubMed ID: 8530650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH.
    Messinis IE; Krishnan M; Kazem R; Khadilkar S; Templeton AA
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):309-14. PubMed ID: 9156040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.